{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:11:49Z","timestamp":1737436309629,"version":"3.33.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1097\/cad.0b013e328223f14d","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T07:01:38Z","timestamp":1187334098000},"page":"1015-1021","source":"Crossref","is-referenced-by-count":2,"title":["Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells"],"prefix":"10.1097","volume":"18","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Ichi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jian","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210227","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1006346624083","article-title":"Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line","volume":"45","author":"Matsumoto","year":"1999","journal-title":"J Neurooncol"},{"key":"R2-4-20210227","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00001813-200404000-00008","article-title":"Down-regulation of human topoisomerase II alpha correlates with altered expression of transcriptional regulators NF-YA and Sp1","volume":"15","author":"Allen","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R3-4-20210227","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gene.2004.07.033","article-title":"Characterization of promoter elements involved in the down-regulation of topoisomerase II alpha expression in a drug-resistant cell line","volume":"342","author":"Saxena","year":"2004","journal-title":"Gene"},{"key":"R4-4-20210227","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF02257459","article-title":"Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein","volume":"20","author":"Sumizawa","year":"1994","journal-title":"Stomata Cell Mol Genet"},{"key":"R5-4-20210227","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0026-895X(24)23189-8","article-title":"ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P","volume":"55","author":"Chen","year":"1999","journal-title":"Mol Pharmacol"},{"key":"R6-4-20210227","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1006\/excr.1998.3938","article-title":"An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells","volume":"240","author":"Chen","year":"1998","journal-title":"Exp Cell Res"},{"key":"R7-4-20210227","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0026-895X(24)13480-3","article-title":"Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P","volume":"51","author":"Sumizawa","year":"1997","journal-title":"Mol Pharmacol"},{"key":"R8-4-20210227","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/bbrc.1995.1344","article-title":"The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance","volume":"208","author":"Gekeler","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"R9-4-20210227","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hyb.1988.7.79","article-title":"Evaluation exporting of three methods for curing hybridomas from mycoplasma contamination","volume":"7","author":"Ravaoarinoro","year":"1988","journal-title":"Hybridoma"},{"key":"R10-4-20210227","first-page":"304","article-title":"Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line","volume":"50","author":"De Jong","year":"1990","journal-title":"Cancer Res"},{"key":"R11-4-20210227","doi-asserted-by":"crossref","first-page":"12696","DOI":"10.1074\/jbc.M300837200","article-title":"Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity","volume":"278","author":"Chikamori","year":"2003","journal-title":"J Biol Chem"},{"key":"R12-4-20210227","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2141.1995.tb03312.x","article-title":"Expression of mdr1, mrp, topoisomerase II alpha\/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias","volume":"89","author":"Beck","year":"1995","journal-title":"Br J Haematol"},{"key":"R13-4-20210227","first-page":"250","article-title":"Detection and treatment of mycoplasma contamination in cultured cells","volume":"26","author":"Jung","year":"2003","journal-title":"Chang Gung Med J"},{"key":"R14-4-20210227","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1128\/AAC.47.9.2892-2896.2003","article-title":"Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein l3","volume":"47","author":"Bosling","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-4-20210227","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1128\/AAC.50.4.1458-1462.2006","article-title":"Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-4-20210227","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00749000","article-title":"Altered DNA topoisomerase II in multidrug resistance","volume":"11","author":"Beck","year":"1993","journal-title":"Cytotechnology"},{"key":"R17-4-20210227","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/0008-5472.CAN-05-3256","article-title":"Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells","volume":"66","author":"Hazlehurst","year":"2006","journal-title":"Cancer Res"},{"key":"R18-4-20210227","first-page":"1064","article-title":"Topoisomerase II as a target of VM-26 and 4\u2032-(9-acridinylamino) methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells","volume":"53","author":"De Jong","year":"1993","journal-title":"Cancer Res"},{"key":"R19-4-20210227","first-page":"3951","article-title":"Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells","volume":"51","author":"Takano","year":"1991","journal-title":"Cancer Res"},{"key":"R20-4-20210227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/bbrc.1997.7115","article-title":"Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase II alpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226","volume":"237","author":"Wang","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-4-20210227","doi-asserted-by":"crossref","first-page":"18961","DOI":"10.1016\/S0021-9258(19)37054-1","article-title":"Cloning and characterization of the 5\u2032-flanking region of the human topoisomerase II alpha gene","volume":"267","author":"Hochhauser","year":"1992","journal-title":"J Biol Chem"},{"key":"R22-4-20210227","first-page":"3860","article-title":"DNA topoisomerase II alpha gene expression under transcriptional control in etoposide\/teniposide-resistant human cancer cells","volume":"55","author":"Kubo","year":"1995","journal-title":"Cancer Res"},{"key":"R23-4-20210227","doi-asserted-by":"crossref","first-page":"16741","DOI":"10.1074\/jbc.271.28.16741","article-title":"Regulation of the human topoisomerase II alpha gene promoter in confluence-arrested cells","volume":"271","author":"Isaacs","year":"1996","journal-title":"J Biol Chem"},{"key":"R24-4-20210227","doi-asserted-by":"crossref","first-page":"37191","DOI":"10.1074\/jbc.M205985200","article-title":"CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase II alpha. Conventional CBF activation domains are not required","volume":"277","author":"Hu","year":"2002","journal-title":"J Biol Chem"},{"key":"R25-4-20210227","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1042\/bj20030032","article-title":"Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors","volume":"374","author":"Magan","year":"2003","journal-title":"Biochem J"},{"key":"R26-4-20210227","doi-asserted-by":"crossref","first-page":"36534","DOI":"10.1074\/jbc.M202605200","article-title":"Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents","volume":"277","author":"Torigoe","year":"2002","journal-title":"J Biol Chem"},{"key":"R27-4-20210227","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5 homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res"},{"key":"R28-4-20210227","first-page":"4124","article-title":"A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation","volume":"56","author":"Taniguchi","year":"1996","journal-title":"Cancer Res"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e328223f14d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:19:43Z","timestamp":1737375583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-200710000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328223f14d","relation":{},"ISSN":["0959-4973"],"issn-type":[{"type":"print","value":"0959-4973"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}